Shenhong Wu

Summary

Affiliation: Stony Brook University
Country: USA

Publications

  1. pmc Bevacizumab increases risk for severe proteinuria in cancer patients
    Shenhong Wu
    Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
    J Am Soc Nephrol 21:1381-9. 2010
  2. pmc Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report
    Sanjaykumar Hapani
    Division of Medical Oncology, Department of Medicine, Stony Brook University, Stony Brook, New York, USA
    J Med Case Reports 4:126. 2010
  3. doi request reprint Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
    Shenhong Wu
    Division of Medical Oncology, Department of Medicine, State University of New York, Stony Brook, NY 11794 9447, USA
    Lancet Oncol 9:117-23. 2008
  4. doi request reprint Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis
    Alyx C Rosen
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd Street, New York, New York 10022, USA
    J Clin Endocrinol Metab 97:1125-33. 2012
  5. doi request reprint Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials
    Vishal Ranpura
    Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
    Acta Oncol 49:287-97. 2010
  6. ncbi request reprint Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis
    Yuxia Jia
    Division of Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 9447, USA
    J Support Oncol 7:211-7. 2009
  7. doi request reprint Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis
    Amna Sher
    Department of Medicine, Stony Brook University School of Medicine, NY, USA
    Acta Oncol 50:997-1005. 2011
  8. doi request reprint Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events
    Shenhong Wu
    Division of Hematology and Oncology, Department of Medicine, Stony Brook University Cancer Center, Stony Brook, New York 11794 9447, USA
    Cancer Invest 29:460-71. 2011
  9. doi request reprint Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis
    Vishal Ranpura
    Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
    Am J Hypertens 23:460-8. 2010
  10. doi request reprint Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis
    Vishal Ranpura
    Department of Medicine, Stony Brook University Cancer Center, 9447 SUNY, Stony Brook, NY 11794, USA
    JAMA 305:487-94. 2011

Collaborators

Detail Information

Publications26

  1. pmc Bevacizumab increases risk for severe proteinuria in cancer patients
    Shenhong Wu
    Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
    J Am Soc Nephrol 21:1381-9. 2010
    ..39). In conclusion, the addition of bevacizumab to chemotherapy significantly increases the risk for high-grade proteinuria and nephrotic syndrome...
  2. pmc Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report
    Sanjaykumar Hapani
    Division of Medical Oncology, Department of Medicine, Stony Brook University, Stony Brook, New York, USA
    J Med Case Reports 4:126. 2010
    ..We report a rare case of eosinophilic pneumonia associated with bleomycin...
  3. doi request reprint Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
    Shenhong Wu
    Division of Medical Oncology, Department of Medicine, State University of New York, Stony Brook, NY 11794 9447, USA
    Lancet Oncol 9:117-23. 2008
    ..The aim of this study is to gain a better understanding of the overall risk of hypertension in patients with cancer who receive sorafenib...
  4. doi request reprint Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis
    Alyx C Rosen
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd Street, New York, New York 10022, USA
    J Clin Endocrinol Metab 97:1125-33. 2012
    ..Therefore, we conducted a systematic review and meta-analysis of the literature to determine the incidence and risk of developing a rash...
  5. doi request reprint Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials
    Vishal Ranpura
    Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
    Acta Oncol 49:287-97. 2010
    ..To determine the risk of ATE including cardiac ischemia and stroke, a systematic review and meta-analysis of published randomized controlled trials (RCTs) was performed...
  6. ncbi request reprint Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis
    Yuxia Jia
    Division of Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 9447, USA
    J Support Oncol 7:211-7. 2009
    ..72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy...
  7. doi request reprint Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis
    Amna Sher
    Department of Medicine, Stony Brook University School of Medicine, NY, USA
    Acta Oncol 50:997-1005. 2011
    ..We performed a meta-analysis of randomized controlled trials (RCT) to determine the effect of the anti-VEGF antibody bevacizumab on anemia in cancer patients treated with chemotherapy...
  8. doi request reprint Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events
    Shenhong Wu
    Division of Hematology and Oncology, Department of Medicine, Stony Brook University Cancer Center, Stony Brook, New York 11794 9447, USA
    Cancer Invest 29:460-71. 2011
    ..Elucidating the molecular basis of these toxicities may lead to clinical benefits by improving patient selection and allowing for the development of effective prevention and management strategies...
  9. doi request reprint Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis
    Vishal Ranpura
    Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
    Am J Hypertens 23:460-8. 2010
    ..We performed a systematic review and meta-analysis of published randomized-controlled clinical trials (RCTs) to assess the risk of high-grade hypertension in cancer patients treated with bevacizumab...
  10. doi request reprint Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis
    Vishal Ranpura
    Department of Medicine, Stony Brook University Cancer Center, 9447 SUNY, Stony Brook, NY 11794, USA
    JAMA 305:487-94. 2011
    ..Currently, the role of bevacizumab in treatment-related mortality is not clear...
  11. doi request reprint Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis
    Sanjaykumar Hapani
    Department of Medicine, Division of Hematology and Medical Oncology, Stony Brook University Medical Center, Stony Brook, NY 11794 9447, USA
    Oncology 79:27-38. 2010
    ..This study was conducted to determine the overall risk of hemorrhage with bevacizumab by a systematic review and meta-analysis of randomized controlled trials (RCT)...
  12. doi request reprint Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis
    David Chu
    Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, NY 11794 9447, USA
    Clin Genitourin Cancer 7:11-9. 2009
    ..86; 95% CI, 3.1-31.31; P < .001) in comparison with controls. There is a significant risk of developing HFSR in patients with cancer receiving sunitinib. Adequate monitoring and intervention are recommended for reducing the toxicity...
  13. doi request reprint Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
    Shobha Rani Nalluri
    Division of Medical Oncology, Department of Medicine, Stony Brook University, Stony Brook, New York 11794, USA
    JAMA 300:2277-85. 2008
    ..Currently, the role of bevacizumab in venous thromboembolism is controversial...
  14. doi request reprint The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
    Yevgeniy Balagula
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Invest New Drugs 30:1773-81. 2012
    ..1-6.2, p < 0.001). Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis...
  15. doi request reprint Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis
    David Chu
    Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    Acta Oncol 47:176-86. 2008
    ..This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib...
  16. doi request reprint Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis
    Xiao Su
    Department of Medicine, AtlantiCare Regional Medical Center, Atlantic City, NJ, USA
    Oncology 77:124-33. 2009
    ..Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash...
  17. doi request reprint The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis
    Benjamin C Garden
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Am Acad Dermatol 67:400-8. 2012
    ..The overall incidence and risk of nail changes associated with the use of epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature...
  18. doi request reprint Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
    Sanjaykumar Hapani
    Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794 9447, USA
    Lancet Oncol 10:559-68. 2009
    ..We did a systematic review and meta-analysis of published randomised controlled trials to assess the overall risk of gastrointestinal perforation associated with bevacizumab treatment...
  19. ncbi request reprint Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis
    Xiaolei Zhu
    Division of Nephrology, SUNY at Stony Brook, NY, USA
    Am J Kidney Dis 49:186-93. 2007
    ..We performed a systematic review and meta-analysis of published clinical trials of bevacizumab to quantify the risk of proteinuria and hypertension...
  20. pmc Novel therapies in genitourinary cancer: an update
    David Chu
    Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
    J Hematol Oncol 1:11. 2008
    ..This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting...
  21. doi request reprint The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
    Kira Minkis
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    J Am Acad Dermatol 69:e121-8. 2013
    ..Dermatologic adverse events such as rash, pruritus, and vitiligo have been reported in trials, with varying incidences. The overall incidence and risk of rash to ipilimumab is unknown...
  22. doi request reprint The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
    Alyssa Fischer
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228 160 E 53rd St, New York, NY, USA
    Invest New Drugs 31:787-97. 2013
    ..These findings underscore the importance of supportive dermatologic care in patients treated with axitinib, in order to maintain quality of life, adherence, and persistence to therapy...
  23. doi request reprint Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
    Alyssa Fischer
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Dermatol Ther 26:135-48. 2013
    ....
  24. doi request reprint Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients
    Samir Kapadia
    Division of Hematology and Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA
    Acta Oncol 52:1202-12. 2013
    ..Severe and fatal hepatotoxicity has been observed in its clinical studies. This analysis was conducted to determine the risk of liver toxicity by a systematic review and meta-analysis of clinical trials...
  25. doi request reprint Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
    Viswanath Reddy Belum
    Dermatology Service, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 E 53rd St, New York, NY 10022, USA
    Invest New Drugs 31:1078-86. 2013
    ..The incidence and risk of HFSR with regorafenib have not been systematically investigated...
  26. ncbi request reprint Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity
    Francisco A Chaves
    David H Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USA
    J Immunol Methods 300:74-92. 2005
    ..The results suggest that similar strategies could be used to increase the stability of other unstable class II molecules for in vitro studies...